AEGiS-CATIE: ANTI-HIV AGENTS: Saquinavir and d4T

ANTI-HIV AGENTS: Saquinavir and d4T

TreatmentUpdate 70, Volume 8, No 6; September, 1996
Sean Hosein

Doctors in Switzerland gave 14 subjects d4T 80 mg/day and saquinavir 1800 mg/day. Before entering this study, half of the subjects had used ddI for about 3 months. Twelve of the subjects had survived at least one life-threatening infection. At the time they entered the study half the subjects had a CD4+ cell count of 33 cells and a CD8+ cell count of 449. None of these subject improved on other older anti-HIV drugs.

Results

One month after entering the study half the subjects saw their CD4+ cell count climb to 65 cells and by the second month, it had reached 90 cells. Similarly, their CD8+ cell count increased to 599 cells during the first month, and in the second it rose to 696 cells. Yet these increases were not statistically significant. During the first month, blood levels of HIV fell to 1/100th their pre-study level, but returned to 1/10th their pre-study level by the end of the second month. This difference was statistically significant.

REFERENCE:

1. Rutschmann O, Kaiser L, Gabriel V, et al. Adding saquinavir to d4T in advanced HIV-1 infection. Th.B.945.

960910
CATE7006

Always watch for outdated information. This article first appeard in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1996 - TreatmentUpdate. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, The Canadian AIDS Treatment Information Exchange, 555 Richmond St. West, Suite 505, Box 1104, Toronto, ON, M5V 3B1 • Phone: 416-203-7122 • Toll Free: 1-800-263-1638 • Fax: 416-203-8284 http://www.catie.ca

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1996. AEGIS.